Skip to main content

BioNTech Records Stupendous Q2 Sales, Earnings Growth; Estimates FY21 COVID-19 Vaccine Revenues Of €15B

BioNTech SE reports Q2 FY21 revenues of €5.31 billion compared to €41.7 million a year ago, primarily due to an increase in the supply of COVID-19 vaccine worldwide. Revenues more than doubled from €2.04 billion sales in Q1 FY21.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.